Bolt Biotherapeutics' GAAP loss for 3 months of 2022 was $23.678 million, down 3.2% from $24.454 million in the prior year. Revenue amounted to $813 thousand. A year earlier, the company had no revenue.
Bolt Biotherapeutics' GAAP loss for 3 months of 2022 was $23.678 million, down 3.2% from $24.454 million in the prior year. Revenue amounted to $813 thousand. A year earlier, the company had no revenue. 
investors.boltbio.com
English (US) 